AI-driven identification of a novel small-molecule modulator targeting SNX10 to inhibit osteoclastic bone resorption
Rattachement africain : au, cn, gb. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Current antiresorptive therapies reduce bone loss by eliminating osteoclasts or inhibiting their formation. However, these approaches could disrupt osteoclast-osteoblast communication and cause serious complications with long-term usage. There is a need for developing new therapies that selectively inhibit resorptive function, while preserving osteoclast-mediated coupling effects to osteoblasts. Sorting nexin 10 (SNX10), an autosomal recessive osteopetrosis (ARO)-associated gene, plays a role mainly in osteoclast bone resorptive function. However, its potential as a target for developing therapeutic agents for bone disorders remains unexplored. In this study, we employed a multi-step approach combining artificial intelligence (AI)-driven virtual screening with high-throughput screening methods and functional assays to identify small molecules targeting SNX10 that inhibit bone resorption without impairing osteoclast formation. Our lead compound AW-006 emerged as the top candidate across all validation methods, selectively inhibiting osteoclast resorptive function while maintaining normal osteoclastogenesis in vitro. Mechanistic analyses indicated that AW-006 interacts with SNX10 and reduces its thermal stability, while molecular docking predicted binding within the PI(3)P-binding pocket and associated conformational changes affecting residues involved in PI(3)P binding and structural integrity. We discovered that SNX10 interacts with the key vesicular trafficking regulator Rab7 in living cells, and AW-006 abnormally enhances this interaction, dysregulating normal podosome belt formation in osteoclasts. Furthermore, the compound's anti-resorptive efficacy was validated in ovariectomized mice, demonstrating its therapeutic potential in estrogen deficiency-induced bone loss. Our study identifies AW-006 as a novel anti-resorptive candidate and highlights SNX10 as a promising therapeutic target for bone disorders.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- AI-driven identification of a novel small-molecule modulator targeting SNX10 to inhibit osteoclastic bone resorption
- Date Crossref
- 23/08/2026
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
The University of Western Australia Molecular Endocrinology and Pharmacology Lab pays non établi dans la noticeUniversité ou école supérieure
-
Wenzhou Medical University Department of Orthopaedic Surgery pays non établi dans la noticeUniversité ou école supérieure
-
Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University pays non établi dans la noticeÉtablissement de santé
-
Jinan University pays non établi dans la noticeUniversité ou école supérieure
-
Harry Perkins Institute of Medical Research pays non établi dans la noticeÉtablissement de santé
-
Shenzhen Institutes of Advanced Technology pays non établi dans la noticeStructure de recherche
-
Shenzhen University of Advanced Technology pays non établi dans la noticeUniversité ou école supérieure
-
King's College London Department of Twin Research and Genetic Epidemiology pays non établi dans la noticeUniversité ou école supérieure
-
School of Biomedical Sciences pays non établi dans la noticeUniversité ou école supérieure
-
School of Molecular Sciences pays non établi dans la noticeUniversité ou école supérieure
-
Medical College Guangzhou Institute of Traumatic Surgery pays non établi dans la noticeUniversité ou école supérieure
-
Monoclonal Antibody Lab pays non établi dans la noticeStructure de recherche
Molecular Endocrinology and Pharmacology Lab — The University of Western Australia, Department of Orthopaedic Surgery — Wenzhou Medical University et Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.